Breast cancer could be detected up to five years before there are any clinical signs of it, using a blood test that identifies the body’s immune response to substances produced by tumour cells, according to new research presented at the 2019 NCRI Cancer Conference today (Sunday).
Cancer cells produce proteins called antigens that trigger the body to make antibodies against them – autoantibodies. Researchers at the University of Nottingham (UK) have found that these tumour-associated antigens (TAAs) are good indicators of cancer, and now they have developed panels of TAAs that are known already to be associated with breast cancer to detect whether or not there are autoantibodies against them in blood samples taken from patients.
In a pilot study the researchers, who are part of the Centre of Excellence for Autoimmunity in Cancer (CEAC) group at the School of Medicine, University of Nottingham, took blood samples from 90 breast cancer patients at the time they were diagnosed with breast cancer and matched them with samples taken from 90 patients without breast cancer (the control group).
They used screening technology (protein microarray) that allowed them to screen the blood samples rapidly for the presence of autoantibodies against 40 TAAs associated with breast cancer, and also 27 TAAs that were not known to be linked with the disease.
Presenting the research at the NCRI Conference, Ms Daniyah Alfattani, a PhD student in the group, said: “The results of our study showed that breast cancer does induce autoantibodies against panels of specific tumour-associated antigens. We were able to detect cancer with reasonable accuracy by identifying these autoantibodies in the blood.”
The researchers identified three panels of TAAs against which to test for autoantibodies. The accuracy of the test improved in the panels that contained more TAAs. The panel of five TAAs correctly detected breast cancer in 29% of the samples from the cancer patients and correctly identified 84% of the control samples as being cancer-free. The panel of seven TAAs correctly identified cancer in 35% of cancer samples and no cancer in 79% of control samples. The panel of nine antigens correctly identified cancer in 37% of cancer samples and no cancer in 79% of the controls.
“We need to develop and further validate this test,” said Ms Alfattani. “However, these results are encouraging and indicate that it’s possible to detect a signal for early breast cancer. Once we have improved the accuracy of the test, then it opens the possibility of using a simple blood test to improve early detection of the disease.”
The researchers are now testing samples from 800 patients against a panel of nine TAAs, and they expect the accuracy of the test to improve with these larger numbers.
“A blood test for early breast cancer detection would be cost effective, which would be of particular value in low and middle income countries. It would also be an easier screening method to implement compared to current methods, such as mammography,” said Ms Alfattani.
The researchers estimate that, with a fully-funded development programme, the test might become available in the clinic in about four to five years.
A similar test for lung cancer is currently being tested in a randomised controlled trial in Scotland, involving 12,000 people at high risk of developing lung cancer because they smoke. They have been randomised to have (or not) an autoantibody blood test called ELISA (Early CDT-Lung). Participants who test positive for the autoantibodies are then followed up with a CT scan every two years in order to detect lung cancer in its early stages when it is easier to treat.
The CEAC group is also working on similar tests for pancreatic, colorectal and liver cancers. Solid tumours like these, as well as lung and breast cancer, represent around 70% of all cancers.
“A blood test capable of detecting any of these cancers at an early stage is the over-riding objective of our work,” concluded Ms Alfattani.
Dr Iain Frame, CEO of NCRI said: “Early diagnosis using simple, non-invasive ways of detecting the first signs of cancer is a key strategic priority for NCRI and something we’d all like to see working in practice. The results from this pilot study for a blood test to detect early breast cancer are promising and build on this research group’s expertise in other cancers, such as lung cancer. It’s obviously early days but we look forward to seeing the results from the larger group of patients that are now being investigated.”
The Latest on: Breast cancer
via Google News
The Latest on: Breast cancer
- Study examines Appalachian Kentucky's breast cancer care disparitieson November 20, 2019 at 9:40 am
It is estimated that nearly 40 percent of women diagnosed with breast cancer will require a mastectomy. For those patients, breast reconstruction surgery is a valuable part of comprehensive breast ...
- GHANTOOT RACING & POLO CLUB TEAM UP WITH MASERATI – PREMIER MOTORS TO DRIVE AWARENESS FOR BREAST CANCERon November 20, 2019 at 9:21 am
Nov 20, 2019 (AB Digital via COMTEX) -- Ghantoot Racing & Polo Club joined hands with Maserati – Premier Motors, in an awe-inspiring initiative to raise awareness about breast-cancer in the UAE, ...
- Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Canceron November 20, 2019 at 6:50 am
A survey of breast cancer survivors was administered online by a hereditary cancer nonprofit organization, Facing Our Risk of Cancer Empowered, from October 2017 to March 2018. Of 1,322 respondents, ...
- Benjamin & Yancy Foundation luncheon honors breast cancer survivorson November 20, 2019 at 5:09 am
The Benjamin & Yancy Foundation recently hosted a luncheon honoring educators who are breast cancer survivors. Relatives and friends gathered at Dooky Chase Restaurant in New Orleans to celebrate the ...
- Study shows gender differences in prognosis predictive utility of breast cancer recurrence scoreon November 20, 2019 at 4:04 am
The TAILORx study published last year offered good news for women with early-stage ER-positive breast cancer who scored at intermediate risk for recurrence according to a genetic assay test. The study ...
- Houston-area community supports breast cancer research at NOBCF luncheonon November 20, 2019 at 2:08 am
This successful luncheon enabled the Foundation to impact the community with energy and enthusiasm and raise awareness about breast cancer. At the luncheon, the Foundation donated $120,000 to three ...
- Biovica's DiviTum Validated as a Dynamic Biomarker in Metastatic Breast Cancer in Collaboration With Institut Curie, Parison November 20, 2019 at 12:32 am
STOCKHOLM, Nov. 20, 2019 /PRNewswire/ -- Biovica, active in cancer biomarkers, today announced that clinical data - demonstrating that DiviTum can be used as a dynamic, non-invasive biomarker for ...
- This teenager's invention could revolutionize radiation therapy for breast cancer patientson November 19, 2019 at 7:35 pm
One day in 2016, 16-year-old Macinley Butson was having dinner with her family in Wollongong, Australia when her father, a health professional, started discussing the side effects of using radiation ...
- Expert: Herbal aids can slow wound healing in breast cancer spread to skinon November 18, 2019 at 10:20 am
Using herbal products to treat breast cancer that's spread to the skin could slow wound healing and interfere with chemotherapy or hormone treatment, an expert warns. Many patients try herbal products ...
- Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expressionon November 18, 2019 at 2:28 am
We sought to determine the frequency and importance of DARPP-32 expression in two large independent cohorts of early stage invasive breast cancer patients, including an additional cohort of HER2 ...
via Bing News